Liposomes Patents (Class 424/450)
-
Patent number: 9987227Abstract: Methods for formulating and compositions of immediate and sustained release liposomal products which comprise a surfactant that interacts with liposomes to effect drug release therefrom, and delivery of such for treatment of respiratory tract infections and other medical conditions, and devices and formulations used in connection with such are described.Type: GrantFiled: October 3, 2014Date of Patent: June 5, 2018Assignee: ARADIGM CORPORATIONInventors: David C. Cipolla, Igor Gonda
-
Patent number: 9987228Abstract: A method for producing porous particles includes (1) a step of preparing a solution of an amphiphilic substance by dissolving the amphiphilic substance in a mixed solvent capable of being freeze-dried, (2) a step of producing a precipitate containing the amphiphilic substance by cooling the solution obtained in step (1) to a temperature equal to or less than a phase separation temperature of the solution, and thereafter holding the solution at the temperature, and (3) a step of producing porous particles by freeze-drying the solution containing the precipitate obtained in the step (2).Type: GrantFiled: November 16, 2015Date of Patent: June 5, 2018Assignee: National Institute for Materials ScienceInventors: Shaoling Zhang, Kohsaku Kawakami, Katsuhiko Ariga
-
Patent number: 9981238Abstract: Embodiments of the present invention are directed to an apparatus and methods for making nucleic acid loaded nanosomes. One embodiment of the present invention directed to an apparatus comprises a first containment means for containing a mixture of an aqueous solution of nucleic acid and a phospholipid solution with a supercritical, critical or near critical fluid. The apparatus further comprises injection means in fluid communication with said first containment means for receiving the mixture and releasing the mixture as a stream into a decompression liquid. The apparatus further comprises a decompression vessel in fluid communication with the injection means for holding a decompression liquid and receiving the mixture as a stream. The stream forms one or more nanosomes loaded with a nucleic acid in the decompression liquid.Type: GrantFiled: August 23, 2011Date of Patent: May 29, 2018Assignee: Aphios CorporationInventor: Trevor Percival Castor
-
Patent number: 9980919Abstract: A pH-responsive nanoparticle made of a pH-responsive polymer and a poly(lactic-co-glycolic acid) by self-assembly includes a polyethylene glycol derivative and a R-Histidine derivative that are subjected to a chemical reaction to form the pH-responsive polymer, wherein the surface electric potential of the pH-responsive nanoparticle is ?25 to 10 mV, such that when a pH value of the pH-responsive nanoparticle is changed from 7.4 to 5.0 depending upon an external environment, a surface zeta potential of the pH-responsive nanoparticle is converted from negative charge to positive charge.Type: GrantFiled: November 4, 2015Date of Patent: May 29, 2018Assignee: NATIONAL TSING HUA UNIVERSITYInventors: Hsin-Cheng Chiu, Wen-Hsuan Chiang, Chia-Chian Hung, Ting-Wei Yu
-
Patent number: 9981058Abstract: The present invention is directed to catheter balloons and balloon catheters with such catheter balloons coated with at least one layer containing at least one antiproliferative, immunosuppressive, anti-angiogenic, anti-inflammatory, anti-restenotic and/or anti-thrombotic agent and a top coat consisting of a polyvinyl alcohol—polyethylene glycol graft copolymer as well as the use of these balloon catheters for the prevention of restenosis.Type: GrantFiled: July 4, 2012Date of Patent: May 29, 2018Assignee: CARDIONOVUM Sp.z.o.o.Inventor: Michael Orlowski
-
Patent number: 9980959Abstract: There is provided pharmaceutical compositions for the treatment of rhinitis by, for example, nasal or ocular administration comprising zwitterionic cetirizine, a polar lipid liposome and a pharmaceutical acceptable aqueous carrier. The compositions are preferably homogeneous in their nature.Type: GrantFiled: April 11, 2012Date of Patent: May 29, 2018Assignee: Biolipox ABInventors: Lena Pereswetoff-Morath, Anders Carlsson
-
Patent number: 9975066Abstract: Layer by layer (“LBL”) construction of products by tangential flow filtration (TFF), or the like, is described, including computer controlled automation of such procedure for production of a multilayer coated core.Type: GrantFiled: May 22, 2015Date of Patent: May 22, 2018Assignee: ARTIFICIAL CELL TECHNOLOGIES, INC.Inventors: James Gorham Boyd, Naveen Palath, Edwin Jonathan Cardenas
-
Patent number: 9974744Abstract: Disclosed are formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs which minimize the side effects of unencapsulated non-steroidal anti-inflammatory drugs while maintaining or improving efficacy. Methods of making and administering the formulations comprising multivesicular liposomes and one or more non-steroidal anti-inflammatory drugs and their use as medicaments are also provided.Type: GrantFiled: March 6, 2013Date of Patent: May 22, 2018Assignee: Pacira Pharmaceuticals, Inc.Inventors: Louie Daniel Garcia, Liangjin Zhu, William Joseph Lambert, Gary Patou
-
Patent number: 9974742Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: February 1, 2016Date of Patent: May 22, 2018Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 9968680Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.Type: GrantFiled: November 24, 2014Date of Patent: May 15, 2018Assignee: CAMURUS ABInventors: Fredrik Joabsson, Margareta Linden, Krister Thuresson, Fredrik Tiberg
-
Patent number: 9969764Abstract: This invention is related to nucleic acid chemistry and describes novel 1,2-dithiolane functionalized nucleoside phosphoramidites (1, Chart 1) and corresponding solid supports (2, Chart 1). In addition to these derivatives, 1,2-dithiolane moiety can also be functionalized to at the various positions of the nucleobase and sugar part as shown in Schemes 1 to 8. The nucleosides of our invention carry a primary hydroxyl for DMTr (4,4?-dimethoxytrityl) function for chain elongation. Furthermore, the phosphoramidite function is attached at the 3?-hydroxyl of the nucleoside. This allows oligonucleotide chain extension under standard DNA and RNA synthesis chemistry conditions and techniques, thus leading to high quality oligonucleotides. These derivatives are useful for introduction of reactive thiol groups either at 3?- or 5?-end of the oligonucleotides on the solid supports such as gold, silver and quantum dots.Type: GrantFiled: April 19, 2016Date of Patent: May 15, 2018Inventors: Suresh C Srivastava, Santhosh K Thatikonda, Sant K Srivastav, Praveen K. Shukla, Alok Srivastava
-
Patent number: 9968583Abstract: The present invention provides a method of manufacture of a liposome composition including a step in which: a liposome dispersion liquid containing a liposome, and further containing cyclodextrin in the liposome internal phase is provided and a step in which an active compound is introduced into said liposome internal phase, and the liposome composition.Type: GrantFiled: March 30, 2010Date of Patent: May 15, 2018Assignee: EISAI R & D MANAGEMENT CO., LTD.Inventors: Hiroshi Kikuchi, Kenji Hyodo, Hiroshi Ishihara
-
Patent number: 9962333Abstract: A system is disclosed for simple, non-invasive, sustained delivery of ophthalmic substances to the interior of the eye, for the prevention and treatment of eye diseases and conditions. Liposomes and inverted micelles are disclosed as suitable vehicles, and timed release of the substances is effected. Delivery methods include coating of a lens or injection into the eye.Type: GrantFiled: August 14, 2014Date of Patent: May 8, 2018Assignee: Board of Trustees of Northern Illinois UniversityInventors: Elizabeth Gaillard, James Dillon, Jason Friedrichs, Tao Xu, Timothy J. Hagen, Devi Kalyan Karumanchi
-
Patent number: 9956300Abstract: The presently disclosed subject matter is directed to compositions, methods, and systems (e.g., platforms) comprising the same, the systems comprising, consisting of, or consisting essentially of micro- and macro-hydrogels that are formed from polypeptide micelles. The systems have enhanced mechanical properties that can be useful in a wide variety of applications, can be used for controlled release of drug-loaded micelles, and can be designed to reversibly assemble and disassemble on demand.Type: GrantFiled: March 18, 2016Date of Patent: May 1, 2018Assignee: Duke UniverityInventors: Gabriel P. Lopez, Ashutosh Chilkoti, Ali Ghoorchian, Joseph R. Simon
-
Patent number: 9956200Abstract: A method of using a composition including dihydroquercetin, as well as optionally ?-tocopherol and/or bisabolol, for treating the effects associated with skin inflammatory disorder, such as those associated with diseases characterized by inappropriate immune response, such as psoriasis, atopic dermatitis and/or urticaria. A process of manufacturing the composition is also described.Type: GrantFiled: February 18, 2015Date of Patent: May 1, 2018Assignee: BIONOOX SUISSE SAInventor: Christian Auclair
-
Patent number: 9950067Abstract: The invention relates to trans carotenoid compounds and salts thereof as well as compositions thereof, methods for making them, and uses thereof. These compounds are useful in improving diffusivity of oxygen between red blood cells and body tissues in mammals including humans.Type: GrantFiled: January 11, 2016Date of Patent: April 24, 2018Assignee: Diffusion Pharmaceuticals, LLCInventors: John L. Gainer, Marc Lanz
-
Patent number: 9950074Abstract: A vehicle composition in the form of a vesicular composition or a particular composition and, optionally, an active agent associated with the vesicle forming components or particles, and folate receptor alpha is used as a delivery system for the transport of components and/or active agents into the cerebrospinal fluid (CSF) and/or brain and/or central nervous system and/or spinal cord. The composition is used for treating of CSF or brain pertaining diseases, disorders or conditions, such as preventing or treating neurological or neurodegenerative diseases, disorders or conditions.Type: GrantFiled: October 12, 2012Date of Patent: April 24, 2018Assignees: Georg-August-Universität Göttingen Stiftung Öffenlichen Rechts, Universitätsmedizin, AllOrphan UGInventors: Robert Steinfeld, Marcel Grapp
-
Patent number: 9951111Abstract: The subject invention pertains to agonist peptides of type I interferons and methods of using the peptides. These peptides are based on the amino acid sequence of the C-terminus region of the type I IFN molecules and are capable of binding to the cytoplasmic domain of type I IFN receptors. Surprisingly, these peptides were found to possess the same or similar biological activity as that associated with the full-length, mature type I IFN proteins, even though these peptides do not bind to the extracellular domain of the type I IFN receptors. In one embodiment, the peptide is a peptide of IFN?. In another embodiment, the peptide is a peptide of IFN?. Exemplified peptides of the invention include those having SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:38, SEQ ID NO:39, and SEQ ID NO:40. The subject peptides have been shown to effect increased resistance to viral infection.Type: GrantFiled: December 11, 2013Date of Patent: April 24, 2018Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATEDInventors: Howard M. Johnson, Chulbul M. Ahmed
-
Patent number: 9949991Abstract: The present invention relates to the use of selective aquaporin inhibitors, e.g., of aquaporin-4 or aquaporin-2, e.g., certain phenylbenzamide compounds, for the prophylaxis, treatment and control of aquaporin-mediated conditions, e.g., glioblastoma and ovarian hyperstimulation syndrome. The invention provides, inter alia, methods of treating or controlling a disease condition mediated by an aquaporin, e.g., diseases or conditions of water imbalance and other diseases.Type: GrantFiled: November 6, 2014Date of Patent: April 24, 2018Assignee: AEROMICS, INC.Inventors: Marc F. Pelletier, Paul Robert McGuirk, George William Farr, Steven Williams
-
Patent number: 9943481Abstract: A method of delivering a pharmaceutical agent into a target organ protected by a blood barrier is provided. The method comprising administering to a subject in need thereof an amount of liposomes which comprise the pharmaceutical agent, the amount and the liposomes are selected such that the liposomes accumulate in cells of an immune system of the subject to thereby generate liposome loaded immune cells, the liposome loaded immune cells become activated and cross the blood barrier, and an effective amount of the pharmaceutical agent is released from the liposomes in the target organ of the subject.Type: GrantFiled: May 25, 2006Date of Patent: April 17, 2018Assignee: BIOrest Ltd.Inventors: Gershon Golomb, Hila Epstein, Eyal Afergan
-
Patent number: 9937247Abstract: Described herein are compositions of matter and methods for treating cancer. The compositions comprise altered human telomerase polypeptides containing T cell epitopes that have been altered to increase immunogenicity. The methods comprise administration of the polypeptides or nucleic acids, such as DNA or RNA encoding the polypeptides, to individuals afflicted with, or at risk of, developing cancer.Type: GrantFiled: February 22, 2017Date of Patent: April 10, 2018Inventor: Maurizio Zanetti
-
Patent number: 9931199Abstract: A method of treating keratoconus in an eye of a patient includes measuring a surface of a cornea of the eye to acquire eye topography data. The method includes, based on the eye topography data, selecting a topographic pattern from topographic patterns displayed in a graphical user interface. The method includes entering vision corrective parameters for the eye of the patient into the graphical user interface. The method includes actuating a processing module to obtain a surgical plan based on the selected topographic pattern and the entered vision corrective parameters. The method includes reviewing intrastromal corneal ring segment (ICRS) implantation surgery parameters specified by the surgical plan and displayed in the user interface. The ICRS implantation surgery parameters include specification of at least one ICRS. The method includes performing implantation surgery of the at least one ICRS into the eye of the patient according to the surgical plan.Type: GrantFiled: May 5, 2015Date of Patent: April 3, 2018Inventor: Roberto Gustavo Albertazzi
-
Patent number: 9931412Abstract: Provided herein is technology relating to theranostic agents and particularly, but not exclusively, to compositions comprising cell-specific theranostic agents and associated methods and systems for using the cell-specific theranostic agents to treat subjects.Type: GrantFiled: February 7, 2014Date of Patent: April 3, 2018Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: Sascha N. Goonewardena, Bertram Pitt, Hong Zong
-
Patent number: 9931410Abstract: Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles.Type: GrantFiled: October 9, 2013Date of Patent: April 3, 2018Assignees: The Brigham and Women's Hospital, Inc., Massachusetts Institute of TechnologyInventors: Pedro M. Valencia, Eric M. Pridgen, Suresh Gadde, Rohit Karnik, Robert S. Langer, Stephen J. Lippard, Omid C. Farokhzad
-
Patent number: 9925251Abstract: The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1.Type: GrantFiled: October 19, 2012Date of Patent: March 27, 2018Assignee: President and Fellows of Harvard CollegeInventors: Tatos Akopian, Olga Kandror, Alfred Lewis Goldberg, Ravikiran M. Raju, Meera Unnikrishnan, Eric J. Rubin
-
Patent number: 9927427Abstract: A method of isolating exosomes includes conducting at least one purification step in the presence of an organic zwitterion having a molecular weight of less than about 350 Daltons, a buffering pK of a negatively charged portion of the organic zwitterion is at least one full pH unit below an operating pH at which the at least one purification step is conducted, and a buffering pK of the positively charged portion of the organic zwitterion is at least one full pH unit above the operating pH.Type: GrantFiled: October 15, 2014Date of Patent: March 27, 2018Assignee: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventor: Peter Stanley Gagnon
-
Patent number: 9919005Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.Type: GrantFiled: November 2, 2016Date of Patent: March 20, 2018Assignee: COUR PHARMACEUTICALS DEVELOPMENT COMPANY, INC.Inventor: Daniel R. Getts
-
Patent number: 9918966Abstract: Compositions and pharmaceutical compositions including one or more selenium-containing COX-2 inhibitors are provided according to aspects of the present invention. Methods of treating a subject having or suspected of having cancer are provided according to aspects of the present invention which include administering a therapeutically effective amount of a pharmaceutical composition including a selenium-containing COX-2 inhibitor.Type: GrantFiled: August 23, 2016Date of Patent: March 20, 2018Assignee: The Penn State Research FoundationInventors: Gavin P. Robertson, Chandagalu D. Raghavendra Gowda, Dhimant H. Desai, Shantu G. Amin
-
Patent number: 9913883Abstract: The current invention involves the administration of negatively charged particles, such as polystyrene, PLGA, or diamond particles, to subjects to ameliorate inflammatory immune responses. Additionally, the present invention describes methods of treating inflammatory diseases by administering these same negatively charged particles.Type: GrantFiled: March 13, 2014Date of Patent: March 13, 2018Assignee: COUR Pharmaceuticals Development CompanyInventor: Daniel Getts
-
Patent number: 9914971Abstract: Congenital diaphragmatic hernia (CDH) is a developmental defect of the diaphragm, causing abdominal viscera to herniate into the thorax. A common genetic cause for CDH and the associated abnormal lung development has not been identified. We have found that human fetal hypoplastic CDH lungs have a specific microRNA miR-200/miR-10a signature, which changes in response to fetal therapy.Type: GrantFiled: October 9, 2015Date of Patent: March 13, 2018Assignee: University of Manitoba, WinnipegInventor: Richard Keijzer
-
Patent number: 9907746Abstract: The present disclosure provides methods for preparing vesicles. In general, these methods include steps of providing a lyophilized lipid product and rehydrating the lyophilized lipid product with an aqueous solution comprising an antigen such that antigen-containing vesicles are formed. The lyophilized lipid product is prepared by dissolving vesicle-forming lipids in a polar-protic water-miscible organic solvent to produce a lipid solution and then lyophilizing the lipid solution. The present disclosure also provides antigen-containing vesicle formulations prepared using these methods. The present disclosure also provides kits that include a lyophilized lipid product in a first container and an aqueous solution comprising an antigen in a second container.Type: GrantFiled: July 6, 2010Date of Patent: March 6, 2018Assignee: Variation Biotechnologies, Inc.Inventors: David E. Anderson, Francisco Diaz-Mitoma, Hoang-Thanh Le
-
Patent number: 9907815Abstract: A method for the polymerization of ?-lipoic acid and ?-lipoic acid derivatives includes preparing an ?-lipoic formulation, exposing the ?-lipoic formulation to an aqueous phase and a gaseous phase at a gas/water interface, and allowing the ?-lipoic formulation to polymerize at the gas/water interface to form a poly(?-lipoic acid) polymer. The ?-lipoic formulation can be an ?-lipoic solution of an ?-lipoic solute and an organic solvent miscible with water, and can also be an ?-lipoic acid or oligomer or polymer thereof in liquid (typically melt) form.Type: GrantFiled: November 21, 2014Date of Patent: March 6, 2018Assignee: The University of AkronInventors: Judit E. Puskas, Emily Q. Rosenthal-Kim
-
Patent number: 9901642Abstract: There are provided for herein novel amine-containing transfection compounds and methods for making and using same. The compounds are generally obtained by reacting a primary amine with an unsaturated compound. Transfection complexes made using the amine-containing transfection compounds in combination with additional compounds to encapsulate biologically active agents such as nucleic acids are also provided for herein. Methods of using the transfection complexes for the in vivo or in vitro delivery of biologically active agents are also described. The transfection complexes of the present invention are highly potent, thereby allowing effective modulation of a biological activity at relatively low doses compared to analogous transfection compounds known in the art.Type: GrantFiled: July 24, 2014Date of Patent: February 27, 2018Assignee: Life Technologies CorporationInventors: Zhiwei Yang, Parul Angrish, Xavier de Mollerat du Jeu, Kristin Wiederholt, Tao Wu
-
Patent number: 9895311Abstract: Provided is a foam-forming formulation and method of treating an infection in a body cavity. The foam-forming formulation contains hydrogen peroxide, monoglyceride crystals, at least one acid and/or buffer which is present in an amount to provide a pH of 3 to 5 within a body cavity, a blowing agent in an amount to blow the foam-forming composition and form a foam, and water. The foam-forming composition is suitable application to body cavity when blown to form the foam and the form degrades at a body temperature to release the hydrogen peroxide to tissues in the body cavity at a pH of 3 to 5. Also provided is a foam-forming composition vehicle for delivering an active agent.Type: GrantFiled: September 24, 2015Date of Patent: February 20, 2018Assignee: Pharmiva ABInventor: Ake Richard Lindal
-
Patent number: 9895298Abstract: The invention concerns a method for extemporaneous and reversible concentration of liposomes, the mixed liposome-cyclodextrin aggregates obtainable by the method, and uses thereof in the pharmaceutical, diagnostic and cosmetic field.Type: GrantFiled: April 30, 2007Date of Patent: February 20, 2018Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)Inventors: Sylviane Leisieur nee Boivin, Valerie Bernat, Genevieve Le Bas, Catherine Ringard nee Lefebvre
-
Patent number: 9895313Abstract: Docetaxel and doxorubicin can be formulated in liposomal pharmaceutical compositions. In various embodiments, the pharmaceutical compositions include (i) a first liposome type comprising a first lipid layer comprising an unsaturated phospholipid, cholesterol or a cholesterol derivative, DC-cholesterol, a cationic lipid, and preferably a pegylated phospholipid, and a first active pharmaceutical ingredient (API) comprising docetaxel in the first lipid layer; and (ii) a second liposome type comprising a second lipid layer, an aqueous interior, and a second API comprising doxorubicin crystallized in the aqueous interior, (iii) where the first liposome type does not comprise doxorubicin and the second liposome type does not comprise docetaxel. The pharmaceutical composition can be used to treat a subject, for example, a human subject having cancer.Type: GrantFiled: March 3, 2016Date of Patent: February 20, 2018Inventors: De-Min Zhu, Guoqiang Chen
-
Patent number: 9885017Abstract: Compositions comprising viral antigens and antigenic peptides corresponding to or derived from Hepatitis C virus (HCV) proteins or fragments thereof, fused to heavy and/or light chain of antibodies, or fragments thereof specific for dendritic cells (DCs) are described herein. Included herein are immunostimulatory compositions (HCV vaccines, HCV antigen presenting dendritic cells, etc.) and methods for increasing effectiveness of HCV antigen presentation by an antigen presenting cell, for a treatment, a prophylaxis or a combination thereof against hepatitis C in a human subject, and methods of providing immunostimulation by activation of one or more dendritic cells, methods to treat or prevent hepatitis C.Type: GrantFiled: January 10, 2014Date of Patent: February 6, 2018Assignees: BAYLOR RESEARCH INSTITUTE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Helene Dutartre, Yves Levy, Jacques Banchereau, Gerard Zurawski
-
Patent number: 9885044Abstract: The present invention provides methods of inhibiting or reducing the growth of cancer cells in a subject, by administering a therapeutic effective amount of Puf-A inhibitor, whereby the symptoms and signs of cancer in the subject are reduced. Also provided are polynucleotides and vectors encoding the shRNAs which target Puf-A expression, which are useful for the treatment of cancer.Type: GrantFiled: June 10, 2016Date of Patent: February 6, 2018Assignee: Chang Gung Memorial Hospital, LinkouInventors: John Yu, Huan-Chieh Cho, Alice Yu
-
Patent number: 9885057Abstract: The invention relates to isolated nucleic acids and rAAV-based compositions, methods and kits useful for treating genetic diseases (e.g., alpha-1 antitrypsin deficiency).Type: GrantFiled: November 25, 2015Date of Patent: February 6, 2018Assignee: University of MassachusettsInventors: Terence Flotte, Christian Mueller, Phillip D. Zamore
-
Patent number: 9879243Abstract: The present invention is directed generally to cell culture media useful for introducing macromolecules and compounds (e.g., nucleic acid molecules) into cells (e.g., eukaryotic cells) in the presence of said media. Cells containing introduced materials can be further cultured in the media. In particular, the invention allows introduction of nucleic acid molecules (e.g., vectors) into cells (particularly eukaryotic cells) and expression of proteins encoded by the nucleic acid molecules in the cells. The invention obviates the need to change the cell culture medium each time a different procedure is performed with the cells (e.g., culturing cells vs. transfecting cells). The invention thus provides efficient and high throughput methods to transform/transfect culture and cells avoiding the need for multiple manipulations and transfers of cells during transfection and expression studies.Type: GrantFiled: August 15, 2013Date of Patent: January 30, 2018Assignee: LifeTechnologies CorporationInventors: Valentina C. Ciccarone, Dale Gruber, Shelly Bennett
-
Patent number: 9878000Abstract: Disclosed is a mucoadhesive nanoparticle delivery system for delivering an immunosuppressant, such as cyclosporine A, to a mucosal site for treatment of a disease or condition involving inflammation or excess immune activity. The system comprises nanoparticles formed from a plurality of linear amphiphilic block copolymers, each having a hydrophobic block comprising polylactide (PLA) and a hydrophilic block comprising dextran. The nanoparticles are surface-functionalized with a mucosal targeting moiety, such as a phenylboronic acid derivative, for targeted delivery and enhanced retention at the mucosal site. Pharmaceutical compositions, methods, and uses thereof comprising the mucoadhesive nanoparticle delivery system are disclosed. The compositions can be administered in an effective amount for treating the disease or condition while substantially preserving or restoring the function and/or integrity of the mucosal lining.Type: GrantFiled: April 29, 2016Date of Patent: January 30, 2018Assignee: UNIVERSITY OF WATERLOOInventors: Frank Xiaofei Gu, Shengyan Liu, Lyndon William James Jones
-
Patent number: 9872834Abstract: Liposomes of a size of less than 200 nanometers target tumors and preferentially deliver imipramine blue to tumors, including brain tumors such as gliomas. The imipramine blue decreases the invasiveness of the tumors, and inhibits tumor metastasis. The liposomes include cholesterol and chemically pure phospholipids that are essentially neutral and contain saturated fatty acids of between 16 and 18 carbon atoms, such as distearoylphosphatidyl choline, and can also include one or more pegylated phospholipids, such as DSPE-PEG.Type: GrantFiled: December 28, 2015Date of Patent: January 23, 2018Assignees: Emory University, Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.Inventors: Jennifer M. Munson, Ravi V. Bellamkonda, Jack L. Arbiser
-
Patent number: 9872831Abstract: The present invention describes oxidized avidin, suitable for inhalation, for conditioning the lung affected by inoperable/diffuse diseases, enabling the targeted delivery of biotinylated therapeutic agents to it.Type: GrantFiled: July 25, 2012Date of Patent: January 23, 2018Assignee: ALFASIGMA S.P.A.Inventor: Rita De Santis
-
Patent number: 9872925Abstract: The present invention relates to a vitamin B6-coupled poly(ester amine) (VBPEA) as a gene carrier and a method for preparing the gene carrier. Moreover, the present invention relates to a gene delivery complex comprising a therapeutic gene coupled to the gene carrier and a pharmaceutical formulation for gene therapy, which comprises the gene delivery complex as an active ingredient. In addition, the present invention relates to gene therapy utilizing the gene carrier, the gene delivery complex or the pharmaceutical formulation. The VBPEA of the invention has a significantly high gene delivery rate compared to existing gene carriers and a complex of the VBPEA with DNA has little or no cytotoxicity and shows a very high in vivo transfection efficiency. In addition, a complex of the VBPEA with siRNA shows high gene silencing efficiency and can induce a high rate of cell death and the inhibition of cell proliferation in cancer cells, suggesting that it can be used for anticancer gene therapy.Type: GrantFiled: February 17, 2014Date of Patent: January 23, 2018Assignee: SNU R&DB FOUNDATIONInventors: Jong Hoon Chung, Shambhavi Pandey, Pankaj Garg, Pill Hoon Choung
-
Patent number: 9872911Abstract: ?-Aminoamidine polymers and methods of preparing a-aminoamidine polymers by reacting by reacting one or more amines with one or more isocyanides and one or more aldehydes are described. Methods of preparing a-aminoamidine polymers from commercially available starting materials are also provided, wherein the starting materials are racemic or stereochemically pure. a-Aminoamidine polymers or salt forms thereof are preferably biodegradable and biocompatible and may be used in a variety of drug delivery systems and for other purposes as well such as, for example, coatings, additives, excipients, plastics, and materials, etc. Given the amino moiety of these ?-aminoamidine polymers, they are particularly suited for the delivery of polynucleotides. Complexes, micelles, liposomes or particles containing the inventive ?-aminoamidine polymers and polynucleotides can be prepared. The inventive ?-aminoamidine polymers may also be used in preparing microparticles for drug delivery.Type: GrantFiled: December 15, 2012Date of Patent: January 23, 2018Assignee: Massachusetts Institute of TechnologyInventors: Arturo Jose Vegas, Kathryn Ann Whitehead, Daniel Griffith Anderson, Robert S. Langer, Joseph R. Dorkin
-
Patent number: 9867799Abstract: The present invention relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof to a patient in need of such a treatment. The invention further relates to a method for treating muscular dystrophy which comprises administering diethyl-[6-(4-hydroxycarbamoyl-phenyl-carbamoyloxy-methyl)-naphthalen-2-yl-methyl]-ammonium chloride or other pharmaceutically acceptable salts and/or solvates thereof in combination with one or more additional anti-inflammatory active agents to a patient in need of such a treatment.Type: GrantFiled: July 13, 2016Date of Patent: January 16, 2018Assignee: ITALFARMACO S.P.A.Inventors: Valentina Saccone, Silvia Consalvi, Pier Lorenzo Puri, Paolo Mascagni
-
Patent number: 9862874Abstract: Methods of introducing a treatment fluid into a subterranean formation having a filtercake deposited thereon, wherein the treatment fluid comprises a base fluid and an inclusion complex comprising a cyclodextrin compound and an acid precursor ester, and wherein the cyclodextrin compound delays hydrolysis of the acid precursor ester; contacting the treatment fluid with the filtercake; and hydrolyzing the acid precursor ester, thereby removing at least a portion of the filtercake.Type: GrantFiled: July 9, 2014Date of Patent: January 9, 2018Assignee: HALLIBURTON ENERGY SERVICES, INC.Inventors: Sunita Sameer Kadam, Rajendra Arunkumar Kalgaonkar
-
Patent number: 9862749Abstract: The present invention relates to a novel analogue antibiotic peptide derived from a CM-MA peptide and a use thereof. Specifically, the novel antibiotic peptides represented by SEQ. ID. NO: 2 to SEQ. ID. NO: 7 (CAM 1 to CMA 6) were synthesized by using a CM-MA antibiotic peptide, in which amphiphilic cecropin A (CA) and magainin 2 (MA) are conjugated, as a template. The synthesized antibiotic peptide exhibits antibiotic activity on gram-positive bacteria and gram-negative bacteria and low cytotoxicity on human red blood cells and human normal cell lines (HaCaT), and thus the antibiotic peptide of the present invention can be favorably used as an active ingredient of an antibiotic agent, a cosmetic composition, a food additive, a feed additive, and a biological pesticide.Type: GrantFiled: January 14, 2015Date of Patent: January 9, 2018Assignee: Industry-Academic Cooperation Foundation, Chosun UniversityInventor: Yoonkyung Park
-
Patent number: 9855247Abstract: The present invention relates to tetracaine based anesthetic formulations and methods of use thereof. The invention further relates to topical formulations of tetracaine and methods of topically anesthetizing body tissues. The present invention also relates to tetracaine based dental anesthetic formulations and methods for anesthetizing the maxillary dental arch using these formulations.Type: GrantFiled: March 2, 2016Date of Patent: January 2, 2018Assignee: St. Renatus, LLCInventor: Mark D. Kollar
-
Patent number: 9857371Abstract: A biomimetic system is provided for use in modeling cell-cell adhesion mechanisms comprising functionalized emulsion droplets. Further, a cell culture medium and a drug delivery system using said biomimetic system are provided.Type: GrantFiled: May 7, 2013Date of Patent: January 2, 2018Assignee: NEW YORK UNIVERSITYInventors: Jasna Brujic, Lea-Laetitia Pontani